LOW LEVELS OF IGM ANTIBODIES AGAINST AN AGE-MODIFIED APOLIPROTEIN B100 PEPTIDE PREDICT CARDIOVASCULAR EVENTS IN NON-DIABETICS

Objectives: Increased glucose levels in diabetics result in advanced glycation endproduct (AGE)-modifications of plaque components. This is considered as an important course of the increased cardiovascular disease in diabetic patients. Immune responses against AGE-modified LDL are associated with cardiovascular disease in diabetic individuals. Methylglyoxal (MGO) is a reactive aldehyde forming AGE. MGO arise from oxidation of glucose, but may also be formed from fatty acid oxidation. We asked if autoantibodies against MGO-modified epitopes of the LDL-protein apoB100 could predict cardiovascular events in a cohort consisting mainly of non-diabetic individuals.